Welcome to the UPF Digital Repository

Genetically modified mice as tools to understand the neurobiological substrates of depression

Show simple item record

dc.contributor.author Robledo, Patricia, 1958-
dc.contributor.author Martín García, Elena, 1975-
dc.contributor.author Aso Pérez, Ester
dc.contributor.author Maldonado, Rafael, 1961-
dc.date.accessioned 2016-01-22T07:54:55Z
dc.date.available 2016-01-22T07:54:55Z
dc.date.issued 2014
dc.identifier.citation Robledo P, Martín-García E, Aso E, Maldonado R. Genetically modified mice as tools to understand the neurobiological substrates of depression. Curr Pharm Des. 2014; 20(23): 3718-37. DOI: 10.2174/13816128113196660741
dc.identifier.issn 1381-6128
dc.identifier.uri http://hdl.handle.net/10230/25634
dc.description.abstract The pathophysiological mechanisms underlying depression are still poorly understood. An initial hypothesis postulated to explain the substrates of depression was based on the involvement of monoaminergic systems. This early theory was proposed from different findings obtained using pharmacological tools and can explain the mechanism of action of the drugs currently used to treat depression. However, more recent studies have revealed that other neurobiological processes different from monoamines also participate in the substrates of depression. These mechanisms include the participation of several neuromodulatory systems, stress-related circuits and neuroplastic changes that could represent a direct substrate for these pathophysiological processes. The lack of selective pharmacological tools for several of these potential targets of depression represents an important limitation to study their potential involvement. In the last two decades, different lines of genetically modified mice have been generated with selective deletions in specific genes related to the control of emotional responses. This review summarizes the main findings that have been obtained with these novel genetic tools to clarify the neurobiological substrates of depression. A particular focus has been devoted to the advances obtained with mice deficient in specific components of the monoaminergic, opioid and cannabinoid system and those with mutations in elements of the hypothalamic-pituitary-adrenal axis.
dc.description.sponsorship This work was supported by the Spanish “Ministerio de Ciencia e Innovación” (#SAF2007-64062 and SAF2011-29864), “Instituto de Salud Carlos III” (RETICS-Red de Trastornos Adictivos-Redes Temáticas de Investigación Cooperativa en Salud: #RD06/0001/0001, #RD06/0001/1004), grants #10/00316 and #10/01708 to PR. Plan Nacional sobre Drogas (PNSD #2009/026), the Marató of TV3, the Catalan Government (SGR2009-00131) and the ICREA Foundation (ICREA Academia-2008)
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Bentham Science Publishers
dc.rights © Bentham Science Publishers. Article published in Robledo P, Martín-García E, Aso E, Maldonado R, Current pharmaceutical design. 23, 2014. The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/
dc.subject.other Depressió psíquica -- Aspectes genètics
dc.subject.other Depressió psíquica -- Etiologia
dc.subject.other Malalties -- Models animals
dc.subject.other Rates (Animals de laboratori)
dc.title Genetically modified mice as tools to understand the neurobiological substrates of depression
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.2174/13816128113196660741
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking